
John Z Metcalfe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10540269/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2022, 60, JCM0190721.	3.9	6
2	Health care seeking patterns of rifampicin-resistant tuberculosis patients in Harare, Zimbabwe: A prospective cohort study. PLoS ONE, 2021, 16, e0254204.	2.5	7
3	Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe, The, 2021, 2, e604-e616.	7.3	32
4	Catastrophic costs among tuberculosisâ€affected households in Zimbabwe: A national health facilityâ€based survey. Tropical Medicine and International Health, 2021, 26, 1248-1255.	2.3	18
5	Distinct lung microbiota associate with HIV-associated chronic lung disease in children. Scientific Reports, 2020, 10, 16186.	3.3	7
6	Xpert Mycobacterium tuberculosis/Rifampicin–Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications. Clinical Infectious Diseases, 2020, 73, e362-e370.	5.8	11
7	Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey. International Journal of Infectious Diseases, 2019, 87, 119-125.	3.3	14
8	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. The Lancet Global Health, 2019, 7, e191-e199.	6.3	53
9	Minority Mycobacterium tuberculosis Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 789-791.	2.9	11
10	Cryptic Microheteroresistance Explains <i>Mycobacterium tuberculosis</i> Phenotypic Resistance. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1191-1201.	5.6	37
11	Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	38
12	Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. BMC Public Health, 2016, 16, 875.	2.9	11
13	Moving Beyond Directly Observed Therapy for Tuberculosis. PLoS Medicine, 2015, 12, e1001877.	8.4	17
14	Genomic Epidemiology of Multidrug-ResistantMycobacterium tuberculosisDuring Transcontinental Spread. Journal of Infectious Diseases, 2015, 212, 302-310.	4.0	34
15	Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients. European Respiratory Journal, 2015, 45, 1504-1506.	6.7	19
16	Analysis of Green Light Committee Implementation and Acquisition of Second-line Drug Resistance. Clinical Infectious Diseases, 2015, 60, 970-970.	5.8	1
17	Drug-Resistant Tuberculosis in High-Risk Groups, Zimbabwe. Emerging Infectious Diseases, 2014, 20, 135-7.	4.3	19
18	Xpert MTB/RIF False Detection of Rifampin-Resistant Tuberculosis from Prior Infection. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1316-1318.	5.6	12

JOHN Z METCALFE

#	Article	IF	CITATIONS
19	Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clinical Microbiology Reviews, 2014, 27, 3-20.	13.6	662
20	Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settings. Lancet Infectious Diseases, The, 2014, 14, 794-795.	9.1	15
21	Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 206-211.	5.6	155
22	Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of Drug-Resistant Tuberculosis in Harare, Zimbabwe. PLoS ONE, 2013, 8, e55872.	2.5	23
23	Genotyping of <i>Mycobacterium tuberculosis</i> : application in epidemiologic studies. Future Microbiology, 2011, 6, 203-216.	2.0	99
24	Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 230-238.	2.1	260
25	Interferon-Î ³ Release Assays for Active Pulmonary Tuberculosis Diagnosis in Adults in Low- and Middle-Income Countries: Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2011, 204, S1120-S1129.	4.0	241
26	Determinants of Multidrug-Resistant Tuberculosis Clusters, California, USA, 2004–2007. Emerging Infectious Diseases, 2010, 16, 1403-1409.	4.3	20
27	Evaluation of Quantitative IFN-γ Response for Risk Stratification of Active Tuberculosis Suspects. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 87-93.	5.6	32